Cargando…

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a

BACKGROUND: Plasma microRNA (miRNA) has become a promising biomarker for detecting cancer; however, it remains uncertain whether miRNA expression levels in plasma reflect those in tumor cells. Our aim was to determine the biological relevance of miR-92a, which has been implicated as an oncomiR in bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohyashiki, Junko H, Umezu, Tomohiro, Kobayashi, Chiaki, Hamamura, Ryoko S, Tanaka, Masami, Kuroda, Masahiko, Ohyashiki, Kazuma
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022817/
https://www.ncbi.nlm.nih.gov/pubmed/21182798
http://dx.doi.org/10.1186/1756-0500-3-347
_version_ 1782196588099141632
author Ohyashiki, Junko H
Umezu, Tomohiro
Kobayashi, Chiaki
Hamamura, Ryoko S
Tanaka, Masami
Kuroda, Masahiko
Ohyashiki, Kazuma
author_facet Ohyashiki, Junko H
Umezu, Tomohiro
Kobayashi, Chiaki
Hamamura, Ryoko S
Tanaka, Masami
Kuroda, Masahiko
Ohyashiki, Kazuma
author_sort Ohyashiki, Junko H
collection PubMed
description BACKGROUND: Plasma microRNA (miRNA) has become a promising biomarker for detecting cancer; however, it remains uncertain whether miRNA expression levels in plasma reflect those in tumor cells. Our aim was to determine the biological relevance of miR-92a, which has been implicated as an oncomiR in both plasma and leukemia cells in patients with acute leukemia and to evaluate whether it could be a novel biomarker for monitoring these patients. RESULTS: We quantified the expression level of miR-92a in both cells and plasma by reverse transcription polymerase chain reaction in 91 patients with acute leukemia. We also determined miR-92a expression levels in peripheral blood mononuclear cells (PBMNC) from normal controls. We compared miR-92a expression in plasma with its expression in leukemia cells. Synthetic anti-miR-92a inhibitor was transfected into Raji and OM9;22 cells, and apoptosis was assessed. For in vivo assessment, 6-week-old female nude mice were injected with U937 cells, and miR-92a expression in plasma and tumors was measured. The level of miR-92a expression in fresh leukemia cells was highly variable compared with PBMNC, but significantly lower compared with CD34-positive cells obtained from healthy volunteers. We also noticed that miR-92a was preferentially expressed in acute lymphoblastic leukemia (ALL) cells in comparison with acute myeloid leukemia (AML) cells. More specifically, cellular miR-92a expression was significantly increased in a subset of ALL cells, and ALL patients with overexpressed miR-92a had poor prognoses. The anti-miR-92a inhibitor-treated Raji and OM9;22 cells revealed an increase of apoptotic cells. Notably, the cell to plasma ratio of miR-92a expression was significantly higher in both AML and ALL cells compared with PBMNC from healthy volunteers. In tumor-bearing mice, the plasma miR-92a level was significantly decreased in accordance with tumor growth, while tumor tissue was strongly positive for miR-92a. CONCLUSIONS: The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients. The inverse correlation of miR-92a expression between cells and plasma and the cell to plasma ratio may be important to understanding the clinical and biological relevance of miR-92a in acute leukemia.
format Text
id pubmed-3022817
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30228172011-01-19 Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a Ohyashiki, Junko H Umezu, Tomohiro Kobayashi, Chiaki Hamamura, Ryoko S Tanaka, Masami Kuroda, Masahiko Ohyashiki, Kazuma BMC Res Notes Research Article BACKGROUND: Plasma microRNA (miRNA) has become a promising biomarker for detecting cancer; however, it remains uncertain whether miRNA expression levels in plasma reflect those in tumor cells. Our aim was to determine the biological relevance of miR-92a, which has been implicated as an oncomiR in both plasma and leukemia cells in patients with acute leukemia and to evaluate whether it could be a novel biomarker for monitoring these patients. RESULTS: We quantified the expression level of miR-92a in both cells and plasma by reverse transcription polymerase chain reaction in 91 patients with acute leukemia. We also determined miR-92a expression levels in peripheral blood mononuclear cells (PBMNC) from normal controls. We compared miR-92a expression in plasma with its expression in leukemia cells. Synthetic anti-miR-92a inhibitor was transfected into Raji and OM9;22 cells, and apoptosis was assessed. For in vivo assessment, 6-week-old female nude mice were injected with U937 cells, and miR-92a expression in plasma and tumors was measured. The level of miR-92a expression in fresh leukemia cells was highly variable compared with PBMNC, but significantly lower compared with CD34-positive cells obtained from healthy volunteers. We also noticed that miR-92a was preferentially expressed in acute lymphoblastic leukemia (ALL) cells in comparison with acute myeloid leukemia (AML) cells. More specifically, cellular miR-92a expression was significantly increased in a subset of ALL cells, and ALL patients with overexpressed miR-92a had poor prognoses. The anti-miR-92a inhibitor-treated Raji and OM9;22 cells revealed an increase of apoptotic cells. Notably, the cell to plasma ratio of miR-92a expression was significantly higher in both AML and ALL cells compared with PBMNC from healthy volunteers. In tumor-bearing mice, the plasma miR-92a level was significantly decreased in accordance with tumor growth, while tumor tissue was strongly positive for miR-92a. CONCLUSIONS: The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients. The inverse correlation of miR-92a expression between cells and plasma and the cell to plasma ratio may be important to understanding the clinical and biological relevance of miR-92a in acute leukemia. BioMed Central 2010-12-24 /pmc/articles/PMC3022817/ /pubmed/21182798 http://dx.doi.org/10.1186/1756-0500-3-347 Text en Copyright ©2010 Ohyashiki et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ohyashiki, Junko H
Umezu, Tomohiro
Kobayashi, Chiaki
Hamamura, Ryoko S
Tanaka, Masami
Kuroda, Masahiko
Ohyashiki, Kazuma
Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
title Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
title_full Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
title_fullStr Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
title_full_unstemmed Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
title_short Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
title_sort impact on cell to plasma ratio of mir-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of mir-92a
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022817/
https://www.ncbi.nlm.nih.gov/pubmed/21182798
http://dx.doi.org/10.1186/1756-0500-3-347
work_keys_str_mv AT ohyashikijunkoh impactoncelltoplasmaratioofmir92ainpatientswithacuteleukemiainvivoassessmentofcelltoplasmaratioofmir92a
AT umezutomohiro impactoncelltoplasmaratioofmir92ainpatientswithacuteleukemiainvivoassessmentofcelltoplasmaratioofmir92a
AT kobayashichiaki impactoncelltoplasmaratioofmir92ainpatientswithacuteleukemiainvivoassessmentofcelltoplasmaratioofmir92a
AT hamamuraryokos impactoncelltoplasmaratioofmir92ainpatientswithacuteleukemiainvivoassessmentofcelltoplasmaratioofmir92a
AT tanakamasami impactoncelltoplasmaratioofmir92ainpatientswithacuteleukemiainvivoassessmentofcelltoplasmaratioofmir92a
AT kurodamasahiko impactoncelltoplasmaratioofmir92ainpatientswithacuteleukemiainvivoassessmentofcelltoplasmaratioofmir92a
AT ohyashikikazuma impactoncelltoplasmaratioofmir92ainpatientswithacuteleukemiainvivoassessmentofcelltoplasmaratioofmir92a